Non-ST Elevation MI: How Long Do We Have for A Coronary Angiography?

This summary discusses the early invasive strategy and the risk of mortality in non-ST-elevation AMI.


Over the past 2 decades, mortality and complications rates have seen a significant reduction thanks to technological and pharmaceutical development, and the increasing experience of health teams. This is especially true when we look at the use of coronary angiography withing 72 hours of symptom onset; in these cases, mortality risk has gone from 3 to 6 months. 

IAM sin elevación del ST: ¿cuánto tiempo tenemos para realizar una coronariografía?

At present, the information is contradicting when it comes to an early invasive strategy. Even though some registries and randomized studies have not shown improvement, this might be the result of different factors, such as the time between symptom onset and the coronary angiography. 

The KAMIR-NIH with 5856 non-ST myocardial infarction patients (NSTEMI) was analyzed: 3919 of these patients had a symptom onset to catheter time (StC) of <48 hours (66.9%) and 1937 a >48-hr StC.

Primary end point was all cause mortality at 3 years and secondary end point was the composite of all cause death, repeat MI or rehospitalization for cardiac failure at 3 years. 

Mean age was 64 and over 70% were men. 

Read also: Is Rehospitalization a Relevant Factor after Aortic Valve Replacement?

Patients presenting <48 hr. StC more often presented hypertension, diabetes, kidney function deterioration, MI, typical angina, angina after the first episode, less cardiac failure, lower GRACE score and better left ventricular function. 

StC was 17.5 hrs. vs 90.8 hrs.

The presence of left main severe stenosis was 5.6%, 3 vessel disease 19%, 2 vessel lesion 28% and one vessel lesion 45%. PCI was done in 85% of cases, CABG in 1.5% and the rest received optimal medical treatment.   

Primary end point at 3 years was 7.3% vs. 13.4% (3-year adjusted HR: 0.76; 95% CI:0.64-0.91; P = 0.002) for <48 hr. StC patient vs >48 hr StC patients respectively. Secondary end point was also in favor of <48 hr StC (12.2% vs. 19.6% 3-year adjusted HR: 0.84; 95% CI: 0.73-0.96; P=0.015).

Read also: Is it Possible to Reduce DAPT Time in Diabetic Patients?

The use of emergency systems was associated to <48 hr StC and lower mortality.

Conclusion

An early invasive strategy based on symptom to catheter time was associated to lower all-cause mortality risk in NSTEMI patients. Seeing as this is a prospective registry, this conclusion should be considered as hypothesis generator to encourage future research. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Early Invasive Strategy Based on the Time of Symptom Onset of Non-ST-Segment Elevation Myocardial Infarction.

Reference: SungA Bae, et al. J Am Coll Cardiol Intv 2023;16:64–75.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2026 | DKCRUSH VIII: IVUS or angiography to guide PCI in complex coronary bifurcations

Intracoronary imaging guidance has become an established recommended strategy in complex coronary lesions. In the specific setting of complex bifurcations, uncertainty remained regarding the...

ACC 2026 | OPTIMAL: IVUS Guidance in PCI of the Unprotected Left Main Coronary Artery

Percutaneous coronary intervention (PCI) is considered an equivalent alternative to coronary artery bypass surgery in patients with left main coronary artery (LMCA) stenosis and...

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...